Literature DB >> 15172043

Treatment of rheumatoid arthritis with etanercept.

Mark C Genovese1, Joel M Kremer.   

Abstract

Etanercept is effective in the treatment of rheumatoid arthritis (RA)when used as monotherapy and in combination with methotrexate(MTX). Radiographic progression of disease was slowed significantly when the drug was used for a 24-month period and was statistically significantly better than MTX. In addition to its use in RA,etanercept is approved by the U.S. Food and Drug Administration for other rheumatologic conditions, including psoriatic arthritis,ankylosing spondylitis, and juvenile chronic arthritis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15172043     DOI: 10.1016/j.rdc.2004.01.004

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  5 in total

1.  Adrenomedullin inhibits IL-1β-induced rheumatoid synovial fibroblast proliferation and MMPs, COX-2 and PGE2 production.

Authors:  Eun-Gyeong Lee; Sang-Il Lee; Han-Jung Chae; Seoung Ju Park; Yong Chul Lee; Wan-Hee Yoo
Journal:  Inflammation       Date:  2011-10       Impact factor: 4.092

2.  Long-term etanercept retention patterns and factors associated with treatment discontinuation: a retrospective cohort study using Canadian claims-level data.

Authors:  Majed Khraishi; Jelena Ivanovic; Yvonne Zhang; Brad Millson; Marie-Josee Brabant; Katia Charland; John Woolcott; Heather Jones
Journal:  Clin Rheumatol       Date:  2018-05-16       Impact factor: 2.980

3.  Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma.

Authors:  Xin Shelley Wang; Qiuling Shi; Loretta A Williams; Nina D Shah; Tito R Mendoza; Evan N Cohen; James M Reuben; Charles S Cleeland; Robert Z Orlowski
Journal:  Leuk Lymphoma       Date:  2014-11-20

4.  Adrenomedullin inhibits MAPK pathway-dependent rheumatoid synovial fibroblast-mediated osteoclastogenesis by IL-1 and TNF-alpha.

Authors:  Hee-Jin Yun; Eun-Gyeong Lee; Sang-Il Lee; Han-Jung Chae; Wan-Hee Yoo
Journal:  Rheumatol Int       Date:  2008-12-31       Impact factor: 2.631

Review 5.  Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years.

Authors:  Mahboob U Rahman; Jacqui Buchanan; Mittie K Doyle; Elizabeth C Hsia; Timothy Gathany; Shreekant Parasuraman; Daniel Aletaha; Eric L Matteson; Philip G Conaghan; Edward Keystone; Désireé van der Heijde; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2011-06-27       Impact factor: 19.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.